The influence of systemic inflammation on inflammation in the brain: Implications for chronic neurodegenerative disease

Brain, Behavior, and Immunity

Volumn 18, Issue 5, 2004, Pages 407-413

  Perry, V Hugh ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Alzheimer's; Infection; Inflammation; Macrophage; Microglia; Neurodegeneration; Parkinson; Sickness

Indexed keywords

AUTACOID; CANCER GROWTH FACTOR; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; BLOOD; BLOOD BRAIN BARRIER; BRAIN; CELL POPULATION; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; ILLNESS BEHAVIOR; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; MICROGLIA; MOLECULAR INTERACTION; NONHUMAN; PARKINSON DISEASE; PATHOLOGY; PRION DISEASE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CHRONIC DISEASE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NEURODEGENERATIVE DISEASES; PRION DISEASES;

EID: 3242710339     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2004.01.004     Document Type: Short Survey

References (22)

1. Aisen P.S., Schafer K.A., Grundman M., Pfeiffer E., Sano M., Davis K.L., Farlow M.R., Jin S., Thomas R.G., Thal L.J. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 289:2003;2819-2826
2. Allan S.M., Rothwell N.J. Cytokines and acute neurodegeneration. Nat. Rev. Neurosci. 2:2001;734-744
3. Banks W.A., Farr S.A., Morley J.E. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation. 3:2002;319-327
4. Betmouni S., Perry V.H., Gordon J.L. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience. 74:1996;1-5
5. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25:2002;532-537
6. Combrinck M.I., Perry V.H., Cunningham C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience. 112:2002;7-11
7. Cunningham C., Deacon R., Wells H., Boche D., Waters S., Diniz C.P., Scott H., Rawlins J.N., Perry V.H. Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur. J. Neurosci. 17:2003;2147-2155
8. Depino A.M., Earl C., Kaczmarczyk E., Ferrari C., Besedovsky H., del Rey A., Pitossi F.J., Oertel W.H. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18:2003;2731-2742
9. Gao H.-M., Liu B., Zhang W., Hong J.-S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24:2003;395-401
10. Henson P.M., Bratton D.L., Fadok V.A. The phosphatidylserine receptor: a crucial molecular switch? Nat. Rev. Mol. Cell. Biol. 2:2001;627-633
11. Holmes C., El-Okl M., Williams A.L., Cunningham C., Wilcockson D., Perry V.H. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry. 74:2003;788-789
12. Jeffrey M., Martin S., Barr J., Chong A., Fraser J.R. Onset of accumulation of PrPres in murine ME7 scrapie in relation to pathological and PrP immunohistochemical changes. J. Comp. Pathol. 124:2001;20-28
13. Kiesecker J.M., Skelly D.K., Beard K.H., Preisser E. Behavioral reduction of infection risk. Proc. Natl. Acad. Sci. USA. 96:1999;9165-9168
14. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci. 25:2002;154-159
15. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:2003;448-452
16. Mattson M.P. Apoptotic and anti-apoptotic synaptic signaling mechanisms. Brain Pathol. 10:2000;300-312
17. McGeer P.L., McGeer E.G. Local neuroinflammation and the progression of Alzheimer's disease. J. Neurovirol. 8:2002;529-538
18. Perry V.H., Cunningham C., Boche D. Atypical inflammation in the central nervous system in prion disease. Curr. Opin. Neurol. 15:2002;349-354
19. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177
20. Sly L.M., Krzesicki R.F., Brashler J.R., Buhl A.E., McKinley D.D., Carter D.B., Chin J.E. Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res. Bull. 56:2001;581-588
21. Williams K., Alvarez X., Lackner A.A. Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia. 36:2001;156-164
22. Wong P.C., Cai H., Borchelt D.R., Price D.L. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5:2002;633-639